ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
We have found that a 6-month course of insulin therapy after a short-term intensive insulin
therapy could shorten the period of hyperglycemia to preserve ß-cell function and further
improve long-term glycemic control in recently diagnosed type 2 diabetes with severe
hyperglycemia (>300 mg/dl, with HBA1C level around 9-11%) in our previous study. We thus
hypothesized that a 6-month course of basal insulin therapy could also help to preserve
ß-cell function in newly diagnosed type 2 diabetes with moderate hyperglycemia (200-300
mg/dl). This prospective study is outpatient-based to evaluate whether 6-month basal insulin
therapy versus oral anti-diabetic treatment (Metformin and sitagliptin) soon after the
diagnosis of type 2 diabetes with moderate hyperglycemia (200-300 mg/dl) is associated with
better ß-cell function reservation. We skip a short-term intensive admission course of
insulin therapy as our previous study in newly diagnosed type 2 diabetes with severe
hyperglycemia.
Phase:
Phase 4
Details
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Treatments:
Insulin Insulin, Globin Zinc Isophane Insulin, Human Metformin Sitagliptin Phosphate